Search

Your search keyword '"Tennagels N"' showing total 77 results

Search Constraints

Start Over You searched for: Author "Tennagels N" Remove constraint Author: "Tennagels N"
77 results on '"Tennagels N"'

Search Results

9. The signalling conformation of the insulin receptor ectodomain

14. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling

15. Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling

18. Inhibitor ?B kinase is involved in the paracrine crosstalk between human fat and muscle cells.

21. 40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

22. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

23. Molecular basis for inhibiting human glucose transporters by exofacial inhibitors.

24. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice.

25. Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.

26. Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice.

27. High-throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry.

28. Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition.

29. Nearly a Century of Insulin at Sanofi: Looking Back Over the Decades of Production and Development.

30. Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog®.

31. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

32. The signalling conformation of the insulin receptor ectodomain.

33. Facile folding of insulin variants bearing a prosthetic C-peptide prepared by α-ketoacid-hydroxylamine (KAHA) ligation.

34. Acute and Repeated Treatment with 5-PAHSA or 9-PAHSA Isomers Does Not Improve Glucose Control in Mice.

35. Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.

37. Progress towards the replacement of the rabbit blood sugar bioidentity assay by an in vitro test for batch release of insulins in quality control.

38. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.

39. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.

40. Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells.

41. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.

42. Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance.

43. BMP4 and BMP7 induce the white-to-brown transition of primary human adipose stem cells.

44. On ceramides, other sphingolipids and impaired glucose homeostasis.

45. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.

46. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.

47. The metabolic and mitogenic properties of basal insulin analogues.

48. Functional annotation of the human fat cell secretome.

49. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.

50. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.

Catalog

Books, media, physical & digital resources